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Introduction: Ticagrelor, the first direct-acting, reversibly binding oral P2Y12 receptor 
antagonist, appears to have a favorable efficacy and safety profile.
Aims: To update the evidence and provide an overview of the available data on ticagrelor.
Evidence review: Peer reviewed articles published and listed under Medline Search, and 
published updated guidelines for pharmacotherapies in acute coronary syndromes were 
reviewed.
Place in therapy: Clinical evidence is increasing to support the use of new thienopyridines 
and the direct-acting P2Y12 receptor in the setting of acute coronary syndromes.
Conclusion: The options for drugs to inhibit the platelet P2Y12 receptor for adenosine 
diphosphate are rapidly expanding. Ticagrelor has shown benefits in clinical trials. Its rapid 
onset of platelet inhibition and short half-life make it an attractive alternative to thienopyridines, 
especially when rapid inhibition of platelet aggregation or its quick reversal are required.
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Core evidence clinical impact summary for ticagrelor and the reduction of major 
adverse cardiac events in patients with acute coronary syndromes
Outcome measure Evidence Implications
Disease-oriented evidence
Clinical
Platelet aggregation Ticagrelor achieved greater 
levels of inhibition than 
did clopidogrel (4 hours 
after dosing [mean ± SD]: 
ticagrelor 90 mg, 79% [±22%], 
ticagrelor 180 mg, 95% [±8%], 
clopidogrel, 64% [±22%])
Better inhibition of platelet 
aggregation may improve 
patient outcomes
Composite of death  
from vascular causes
9.8% of patients receiving 
ticagrelor compared with 
11.7% of those receiving 
clopidogrel (HR), 0.84; 95% 
confidence interval [CI], 
0.77–0.92; P , 0.001).
in patients with ACS with 
or without ST-segment 
elevation, treatment with 
ticagrelor as compared with 
clopidogrel significantly 
reduced the rate of death 
from vascular causes
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Introduction
The use of dual antiplatelet therapy has been fundamental 
in improving outcomes in patients with atherothrombotic 
events, and the combined use of aspirin and thienopyridines 
has been extensively studied. Although clopidogrel, the main 
type of thienopyridine in use today, has been shown to be 
beneficial, it also has limitations – specifically, the variability 
in response to platelet inhibition that some patients may 
have due to metabolic or pharmacologic interactions and 
genetic polymorphisms. These limitations combined with 
clopidogrel’s association with decreased efficacy have served 
as the rationale for the development of new P2Y12 agents, 
which appear to have superior pharmacodynamic profiles.
(Continued)
Outcome measure Evidence Implications
Patients with ACS undergoing 
planned invasive evaluation
Cardiovascular death, Mi,  
or stroke occurred in  
fewer patients in the  
ticagrelor group than in  
the clopidogrel group  
(569 [event rate at 360 days,  
9.0%] vs 668 [10.7%],  
HR 0.84, 95% Ci: 0.75–0.94; 
P = 0.0025)
when using a more potent 
ADP inhibitor in the setting 
of ACS and following an 
invasive strategy, ticagrelor 
appears to be the better 
option
Patient-oriented evidence
Bleeding complications No significant difference in  
the rates of major bleeding 
was found between the 
ticagrelor and clopidogrel 
groups (11.6% and 11.2%, 
respectively; P = 0.43), but 
ticagrelor was associated  
with a higher rate of major  
bleeding not related to  
CABG (4.5% vs 3.8%; 
P = 0.03), including more 
instances of fatal intracranial 
bleeding
in patients treated with 
ticagrelor compared to 
clopidogrel there is no 
increase in the rate of overall 
major bleeding but there 
is an increase in the rate 
of non-procedure-related 
bleeding
Effects on cardiac rhythm  
and conduction
The incidence of ventricular 
pauses .3 seconds  
identified during Holter 
monitoring during the first 
week of therapy was 5.8% 
for patients given ticagrelor 
and 3.6% for patients given 
clopidogrel (P = 0.01).
Precaution in patients with 
bradyarrhythmias
Dyspnea Absolute 6% increase in 
the incidence of dyspnea in 
patients treated with ticagrelor
it may affect long-term 
compliance if the agent is  
to be used routinely
Quality of life measures Not available
Economic evidence Not available
Abbreviations: CABG, coronary artery bypass graft; ACS, acute coronary syndromes; ADP; 
adenosine-diphosphate; MI, myocardial infarction; HR, hazard ratio; CI, confidence interval.
Ticagrelor, the first direct-acting, reversibly binding 
oral P2Y12 receptor antagonist, appears to have a favorable 
efficacy and safety profile. Results of the Platelet Inhibition 
and Patient Outcomes (PLATO) trial,1 showed patients with 
acute coronary syndromes (ACS) had improved outcomes with 
ticagrelor compared with clopidogrel. Currently, ticagrelor is 
being reviewed by the US Food and Drug Administration 
(FDA) as a P2Y12 receptor blocker for the treatment of 
patients with coronary artery disease. (To date, landmark trials 
have evaluated its use only in ACS.) Its initial approval in the 
United States was delayed by the FDA because of a lack of 
benefit observed in US patients. As with any pharmacologic 
agent, ticagrelor has its advantages and limitations. Given its Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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lack of extensive clinical use outside the tight constraints of 
clinical trials, there are many unknowns, and routine use of the 
drug in patients outside of clinical trials will require careful 
postmarketing surveillance. The following review describes 
the available evidence for ticagrelor.
Acute coronary syndromes  
and the need for antithrombin  
and antiplatelet therapies
The management of unstable angina and non-ST–segment–
elevation myocardial infarction (UA/NSTEMI) has evolved 
substantially in recent years. New antithrombotic options 
include low-molecular-weight heparins, Xa inhibitors, direct 
thrombin inhibitors, thienopyridines, and glycoprotein (GP) 
IIb/IIIa antagonists. In addition, the use of percutaneous 
interventions in patients with UA/NSTEMI has become a 
dominant strategy, particularly at tertiary care centers. Recent 
data from the Can Rapid Risk Stratification of Unstable 
Angina Patients Suppress Adverse Outcomes with Early 
Implementation of the ACC/AHA Guidelines (CRUSADE)2 
registry show that fully 86% of patients with UA/NSTEMI 
will be sent to the catheterization laboratory, with 70% of 
patients undergoing angiography within 48 hours and 55% 
ultimately undergoing percutaneous coronary intervention 
(PCI) – 46% of them within 48 hours.
Procedural anticoagulation is believed to be an impor-
tant adjunctive therapy for PCI. Traditionally, the presence 
of thrombus has been viewed as a main risk factor for 
adverse outcomes after interventional   procedures. Results 
of a number of studies have shown that angiographic evi-
dence of pre-existing thrombus before angioplasty, although 
infrequent (,4%), may double or triple the likelihood of 
procedural failure.3–5 Patients with unstable angina undergo-
ing angioplasty in the setting of angiographically demon-
strable thrombus are also at higher risk of abrupt vessel 
closure and have worse in-hospital clinical outcomes.6
Thus, we have a paradox. On the one hand, we are 
performing more PCIs more often in these patients. On the 
other hand, we have an ever-expanding therapeutic arma-
mentarium to apply in these complex clinical circumstances. 
Unfortunately, at initial presentation, we can never know 
exactly what is going to ensue later in these patients’ hospital 
course. Much of the controversy surrounding modern-day 
management of these patients is not so much about the 
specific choice of agent or strategy, but rather how to use 
these agents most effectively in a clinical environment 
where patients are sent to the catheterization laboratory – 
often urgently – and then may later require percutaneous or 
surgical revascularization.
The role of platelets
Platelets contribute to arterial thrombosis in 5 main ways: 
adhesion to connective tissue surfaces; activation and 
granule release; platelet-platelet aggregation; thrombin 
generation because of a catalytic surface; and localization 
and stimulus for the activation of inflammatory cells. 
Complex glycoprotein molecules found on the surface 
of the platelet membrane act as receptors that mediate 
attachment to collagen and other platelets through 
intermediary molecules. An exposed connective tissue 
surface containing collagen or adherent von Willebrand 
factor (vWF) or an adherent platelet with exposed GP IIb/
IIIa receptors that bind fibrinogen or vWF offer a site of 
attachment for additional platelets. After attachment, the 
platelet recognizes a stimulus for activation and undergoes 
a metamorphosis, becoming spiculated in appearance and 
altering its membrane to act as a catalyst for coagulation 
enzymes. Activation also triggers the release of storage 
granules and increased exposure of GP IIb/IIIa, furthering 
the attachment of additional platelets. Platelet shape 
change, membrane alteration, granule release, and receptor 
exposure are all part of the activation process. In addition, 
the activation process exposes attachment sites for 
inflammatory cell activators, which is an important step in 
the initiation of healing but is also partly responsible for the 
systemic inflammation that accompanies thrombosis.7–9
The interaction between platelet receptors and available 
agents for inhibition is shown in Figure 1.
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Figure 1 Schematic of platelets and the sites of action of antiplatelet agents.
Abbreviations: AA, arachidonic acid; ADP, adenosine diphosphate; ASA, aspirin; COX, 
cyclooxygenase; GP, glycoprotein; TXA2, thromboxane; vwF, von willebrand factor.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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Acute coronary syndromes, 
guidelines, and the first 
thienopyridines
As discussed above, platelet activation plays a critical role in 
thrombus formation during plaque rupture leading to ACS. 
A main element is the activation of the adenosine-diphosphate 
(ADP) receptor. The ADP receptor binds to the G protein–
coupled receptors P2Y12 (Gi/adenylyl cyclase pathway) and 
P2Y1 (Gq/phospholipase C/Ca2 pathway), initiating platelet 
shape change and activation. More importantly, binding to the 
P2Y12 receptor amplifies platelet response to other stimuli, 
such as TXA2 and thrombin.10
Available agents for inhibiting purinergic platelet 
activation include the oral thienopyridines ticlopidine and 
clopidogrel. Both drugs require hepatic metabolism to form 
an active metabolite that may then irreversibly bind to the 
P2Y12 receptor.11 Surprisingly, mild liver dysfunction does 
not appreciably affect conversion to the active metabolite.12 
However, response variability can be affected by absorption, 
concurrent drug administration, or obesity.13,14
Maximal effect on bleeding time is seen after 5 days of 
ticlopidine administration or after 3 to 5 days of clopidogrel 
administration and can be hastened by the application of 
a loading dose. The effects on bleeding time persist for 
about 1 week after discontinuation of either drug. On the 
basis of these observations, the 2007 American College 
of Cardiology/American Heart Assocation (ACC/AHA) 
guidelines for the care and management of UA/NSTEMI 
have listed combination antiplatelet therapy with aspirin and 
clopidogrel (giving the choice of either a 300- or 600-mg 
loading dose) as a Class Ia recommendation.15
In patients who are to be treated medically, clopidogrel 
should be given at the time that decision is made. In high-risk 
patients who have indications for early invasive management, 
either a preprocedural clopidogrel bolus or the institution 
of GPI is recommended. The combination of all 3 forms of 
platelet inhibition is labeled a Class IIa recommendation. The 
duration of therapy is not clearly but rather softly stated as 
“ideally for one year”.
Strong backing of the guidelines is necessary, because 
clopidogrel is being underused. This is almost certainly the 
result of bleeding concerns should patients later be referred 
for coronary artery bypass graft (CABG) surgery. Tricoci and 
colleagues16 studied 61,052 patients with high-risk NSTE-
ACS (defined as the presence of positive cardiac markers, 
ischemic ST-segment changes, or both) and   evaluated 
temporal trends of clopidogrel use at discharge since the 
update of the 2002 ACC/AHA guidelines. They found that 
only 34,319 patients (56.2%) received clopidogrel at hospital 
discharge. Although 96.3% of patients who underwent PCI 
received clopidogrel at hospital discharge, only 42.8% of 
patients who did not undergo cardiac catheterization and 
23.5% of patients who underwent CABG went home on 
clopidogrel, despite being admitted to the hospital with 
high-risk UA/NSTEMI. Apart from PCI, variables favoring 
receiving clopidogrel at discharge included previous PCI 
or CABG, stroke, hypercholesterolemia, elevated cardiac 
markers compatible with a myocardial infarction (MI), and 
inpatient care by a cardiologist. The authors concluded that 
while there was in increase in prescribing clopidogrel to 
NSTE-ACS patients at hospital discharge who had been 
treated with medical therapy alone or in those who had 
undergone CABG surgery, most of these NSTE-ACS patients 
still do not receive clopidogrel at hospital discharge.16
The guidelines recommend that dual antiplatelet therapy 
using aspirin and clopidogrel be administered to the majority 
of patients with ACS, including those undergoing PCI.
Clopidogrel alternatives
Because it is often difficult to achieve an adequate pretreat-
ment goal with clopidogrel in clinical practice, more rapid 
achievement of platelet P2Y12 inhibition may improve 
patient outcomes. Prasugrel, ticagrelor, and cangrelor are 
platelet P2Y12 receptor antagonists currently in   development 
that offer faster-acting inhibition of ADP-induced   platelet 
aggregation. These agents act on the same platelet   receptor 
as clopidogrel but are distinguished by their routes of 
administration, reversibility, and pharmacodynamic 
properties.
Ticagrelor is the first reversibly binding oral P2Y12 
  receptor antagonist that blocks ADP-induced platelet 
aggregation. Unlike thienopyridines, which irreversibly 
bind to the P2Y12 receptor for the lifetime of the platelet, 
  ticagrelor binds reversibly to the receptor and exhibits 
rapid onset and offset of effect, which closely follow drug 
exposure levels. Unlike thienopyridines, ticagrelor does 
not require metabolic activation. It is quickly absorbed and 
exhibits a rapid antiplatelet effect, with higher and more 
consistent levels of inhibition of platelet aggregation (IPA) 
maintained across the dosing interval than with clopidogrel. 
Levels of IPA decrease with plasma drug levels after 
discontinuation. In the phase II Dose confIrmation Study 
assessing   anti-  Platelet Effects of AZD6140 vs clopidogRel 
in non–ST-segment Elevation myocardial infarction-2 
(DISPERSE-2) trial of 990 patients with NSTEMI-ACS, 
ticagrelor treatment with 90 mg and 180 mg twice daily Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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showed comparable rates of major and minor bleeding 
compared with clopidogrel (75 mg), with numerically fewer 
MIs. Ticagrelor resulted in greater IPA in clopidogrel-naïve 
patients and produced substantial additional reductions in 
platelet aggregation activity in patients pretreated with 
clopidogrel. Ticagrelor treatment was also well tolerated 
in patients in the DISPERSE-2 trial17 and discontinuation 
rates were comparable to those observed for clopidogrel 
(Table 1).
An increased risk of mild to moderate dyspnea and mostly 
asymptomatic ventricular pauses were observed in phase II 
studies of ticagrelor. The mechanisms for these effects are 
currently being investigated but appear to be adenosine 
mediated. The side effects identified during clinical trials 
are shown in Table 2.
The efficacy and safety of ticagrelor were further evaluated 
in the phase III PLATO trial,1,18 involving more than 18,000 
patients with ACS, including both ST-elevation and non-
ST–elevation ACS.17–19 The rhythm abnormalities identified 
using ticagrelor at the recommended maintenance dose of 
90 mg twice a day are shown in (Table 3).
Pharmacodynamics  
and pharmacokinetics of ticagrelor
In a double-blind, parallel-group study conducted to assess 
the pharmacodynamics, pharmacokinetics, and safety of 
ticagrelor, 200 patients with atherosclerosis were randomly 
assigned to receive 50, 100, or 200 mg of ticagrelor twice 
daily, 400 mg of ticagrelor once daily, or 75 mg of   clopidogrel 
once daily for 28 days.19 All groups received aspirin 
(75–100 mg, once daily). Patients receiving either dosage 
of ticagrelor had rapidly and nearly completely inhibited 
ADP-induced platelet aggregation after the initial dose 
(day 1) and at day 28. On day 1, peak final-extent IPA was 
observed 2 to 4 hours after ticagrelor administration, whereas 
  clopidogrel only minimally inhibited platelet aggregation 
(mean percentage IPA , 20% at all time points). Four 
hours after administration at steady state, the 3 higher doses 
of ticagrelor produced comparable final-extent IPA, and 
Table 1 Clinical end points: number of events
End point  Clopidogrel 
 75 mg daily  
(n = 327)
Ticagrelor  
90 mg 
twice daily  
(n = 334)
P value vs 
clopidogrel
Through 4 weeks, n (%)
All-cause death 2 (0.6) 6 (1.9) 0.18
Cv death 2 (0.6) 6 (1.9) 0.18
Mi 11 (3.5) 7 (2.2) 0.34
Stroke  1 (0.3) 2 (0.6) 0.57
SRi 2 (0.6) 2 (0.6) 0.99
Ri 5 (1.6) 10 (3.2) 0.21
Cv death/Mi/stroke 12 (3.8) 14 (4.3) 0.71
Through 12 weeks, n (%)
All-cause death 4 (1.3) 7 (2.4) 0.38
Cv death 4 (1.3) 6 (1.9) 0.54
Mi 15 (5.6) 12 (3.8) 0.41
Stroke  1 (0.3) 2 (0.6) 0.57
SRi 3 (1.4) 5 (2.3) 0.50
Ri 9 (3.0) 13 (4.9) 0.29
Cv death/Mi/stroke 17 (6.2) 19 (6.0) 0.90
Adapted from J Am Coll Cardiol. 2007;50:1844–1851.17
Abbreviations:  Cv,  cardiovascular;  Mi,  myocardial  infarction;  Ri,  recurrent 
ischemia; SRi, severe recurrent ischemia.
Table 2 Crude incidence rates of adverse events
Event Clopidogrel  
75 mg daily  
(n = 327)
Ticagrelor  
90 mg 
twice daily  
(n = 334)
P value vs 
clopidogrel
Dyspnea 21 (6.4) 35 (10.5) 0.07
Chest pain 29 (8.9) 25 (7.5) 0.57
Headache 28 (8.6) 32 (9.6) 0.69
Nausea 11 (3.4) 22 (6.6) 0.07
Dyspepsia 9 (2.8) 16 (4.8) 0.22
insomnia 9 (2.8) 18 (5.4) 0.12
Diarrhea 11 (3.4) 10 (3.0) 0.83
Hypotension 2 (0.6) 14 (4.2) 0.004
Dizziness 10 (3.1) 14 (4.2) 0.53
Syncope 2 (0.6) 4 (1.2) 0.69
Rash 2 (0.6) 3 (0.9) 1.00
Adapted from J Am Coll Cardiol. 2007;50:1844–1851.17
Table  3 Arrhythmia  events  detected  on  continuous  electro-
cardiography
Clopidogrel  
75 mg  
once daily,  
n = 297, n (%)
Ticagrelor  
90 mg  
twice daily,  
n = 305, n (%)
P values*
VTs
Patients with sustained  
vT . 30 seconds
1 (0.3) 0 (0.0) 0.49
Patients with at least  
1 NSvT
65 (22%) 67 (22%) 1.00
Patients with at least  
1 triplet
93 (31%) 89 (29%) 0.59
Ventricular pauses
Patients with at least  
1 pause .2.5 seconds
13 (4.3%) 17 (5.5%) 0.58
Patients with .3 
episodes of pauses  
.2.5 seconds
1 (0.3%) 6 (2.0%) 0.12
Patients with at least  
1 pause .5 seconds
1 (0.3%) 5 (1.6%) 0.22
Adapted from J Am Coll Cardiol. 2007;50:1844–1851.17
Abbreviations:  NSvT,  nonsustained  ventricular  tachycardia;  vT,  ventricular 
tachycardia.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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ticagrelor was generally well tolerated. All bleeding events, 
except in 1 patient receiving 400 mg daily, were minor and 
of mild-to-moderate severity. In this study, ticagrelor doses at 
100 and 200 mg twice daily were well tolerated and superior 
in antiplatelet efficacy to the 50-mg dosage of ticagrelor and 
to clopidogrel.19
The pharmacologic characteristics of clopidogrel, 
prasugrel, and ticagrelor are shown in (Table 4).
Ticagrelor has greater mean 
inhibition of platelet aggregation 
and further suppresses platelet 
aggregation in clopidogrel-
pretreated patients
A substudy20 of the DISPERSE-2 trial compared the anti-
platelet effects of ticagrelor and clopidogrel and assessed 
the effects of ticagrelor in clopidogrel-pretreated patients. 
Although it has been well documented that clopidogrel com-
bined with aspirin reduces cardiovascular events in patients 
with ACS, patients with poor inhibition of platelet aggrega-
tion with clopidogrel may be less protected. In the substudy, 
patients were randomly assigned to receive either 90 mg of 
ticagrelor twice a day, 180 mg of ticagrelor twice a day, or 
75 mg of clopidogrel once a day for up to 12 weeks in a 
double-blind, double-dummy design. One half of the patients 
also receiving ticagrelor also received a 270-mg loading 
dose. Patients who received clopidogrel were given a 300-mg 
loading dose, unless they had already been treated with 
clopidogrel. ADP-induced platelet aggregation was assessed 
by optical aggregometry on day 1 and at 4-week intervals. It 
was found that ticagrelor inhibited platelet aggregation in a 
dose-dependent fashion and that both doses achieved greater 
levels of inhibition than did clopidogrel (at 4 weeks, 4 hours 
after dosing [mean ± SD]): ticagrelor 90 mg, 79% [±22%], 
ticagrelor 180 mg, 95% [±8%], clopidogrel, 64% [±22%]). 
Ticagrelor also produced further suppression of platelet 
aggregation in patients previously treated with clopidogrel. 
The authors concluded that ticagrelor exhibited greater mean 
IPA than a standard regimen of clopidogrel in ACS patients 
and that ticagrelor further suppressed platelet aggregation in 
clopidogrel-pretreated patients.20
Building the evidence:  
the DISPERSE-2 trial
The goal of the DISPERSE-2 trial17 was to compare the 
safety and initial efficacy of ticagrelor with clopidogrel in 
patients with NSTE-ACS. Evidence had shown that ticagre-
lor achieves higher mean levels of platelet inhibition than 
does clopidogrel in patients with stable coronary artery 
disease. A total of 990 patients with NSTE-ACS, treated 
with aspirin and standard therapy for ACS, was randomized 
in a 1:1:1 double-blind fashion to receive either twice-
daily ticagrelor (90 mg), once-daily ticagrelor (180 mg), 
or   clopidogrel (300-mg loading dose plus 75 mg once 
daily) for up to 12 weeks. When analyzed, the primary end 
point, given by the Kaplan–Meier rate of major or minor 
bleeding through 4 weeks, was 9.8% in the ticagrelor 
90-mg group, 8.0% in the ticagrelor 180-mg group, and 
8.1% in the clopidogrel group (P = 0.43 and P = 0.96, 
respectively, vs clopidogrel). Major bleeding rates were 
6.9%, 7.1%, and 5.1%, respectively (P = 0.91 and P = 0.35, 
respectively, vs clopidogrel). Although not statistically 
significant, favorable trends were seen in the Kaplan–Meier 
rates of MI over the entire study period (5.6%, 3.8%, and 
2.5%, respectively; P = 0.41 and P = 0.06, respectively, 
vs clopidogrel). In a post hoc analysis of continuous 
electrocardiograms, asymptomatic ventricular pauses 
(.2.5 seconds) were more common, especially in the 
ticagrelor 180-mg group (4.3%, 5.5%, and 9.9%, respec-
tively; P = 0.58 and P = 0.01, respectively, vs clopidogrel). 
In this initial experience, when compared with clopidogrel, 
there was no difference in major bleeding, an increase in 
minor bleeding at the higher dose, and encouraging results 
for the secondary end point of MI17 (Figure 2).
Table 4 Pharmacologic properties of a selection of antiplatelet agents
Drug Action Aggregation 
to ADP
Route of 
administration
Metabolism Time to 
peak effect
Offset of 
action
Clopidogrel  
300 mg
iRR ∼30% Oral Esterase inactivation and two-step 
hepatic CYP-dependent activation
∼4 hours ∼5 days
Prasugrel  
60 mg
iRR 75%–80% Oral Esterase inactivation and one-step  
CYP-dependent activation (liver or gut)
1–2 hours ∼5 days
Ticagrelor R 75%–80% Oral None required 1–2 hours 1–2 days32 
Adapted from. Circulation. 2009;120:2577–258532 and Vasc Health Risk Manag. 2010;6:419–429.33
Abbreviations: ADP, adenosine-diphosphate; iRR, irreversible; R, reversible.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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Ticagrelor in the setting  
of acute coronary syndromes:  
the PLATO study
The PLATO study1 is a multicenter, double-blind, ran-
domized trial in patients with ACS comparing 2 treatment 
strategies: ticagrelor (180-mg loading dose, 90 mg twice 
daily thereafter) and clopidogrel (300- to 600-mg loading 
dose, 75 mg daily thereafter). The goal was to evaluate the 
impact of a more potent platelet inhibitor for the prevention 
of cardiovascular events. A total of 18,624 patients admitted 
to the hospital with an ACS, with or without ST-segment 
elevation, was evaluated. At 12 months, the primary end 
point – a composite of death from vascular causes, MI, or 
stroke – had occurred in 9.8% of patients receiving ticagrelor 
compared with 11.7% of those receiving clopidogrel (hazard 
ratio [HR], 0.84; 95% confidence interval [CI], 0.77– 0.92; 
P , 0.001). Predefined hierarchical testing of secondary end 
points showed significant differences in the rates of other 
composite end points, as well as in MI alone (5.8% in the 
ticagrelor group vs 6.9% in the clopidogrel group; P = 0.005) 
and death from vascular causes (4.0% vs 5.1%; P = 0.001) 
but not stroke alone (1.5% vs 1.3%; P = 0.22). The rate of 
death from any cause was also reduced with ticagrelor (4.5% 
vs 5.9%; P , 0.001). No significant difference in the rates of 
major bleeding was found between the ticagrelor and clopi-
dogrel groups (11.6% and 11.2%, respectively; P = 0.43), 
but ticagrelor was associated with a higher rate of major 
bleeding not related to CABG (4.5% vs 3.8%; P = 0.03), 
including more instances of fatal intracranial bleeding and 
fewer instances of fatal bleeding of other types.
From the PLATO study, it was concluded that in patients 
with ACS with or without ST-segment elevation, treatment 
with ticagrelor as compared with clopidogrel significantly 
reduced the rate of death from vascular causes, MI, or stroke, 
without an increase in the rate of overall major bleeding 
but with an increase in the rate of non-procedure–related 
bleeding.1
Ticagrelor in patients with ACS 
undergoing planned invasive 
evaluation
The PLATO study also evaluated the impact of an invasive 
strategy and the concomitant administration of ticagrelor 
versus clopidogrel. At randomization, an invasive strategy 
was planned for 13,408 (72%) of 18,624 patients. In a 
double-blind, double-dummy study, patients were randomly 
assigned in a 1:1 ratio to receive ticagrelor and placebo 
(180-mg loading dose followed by 90 mg twice a day) or 
to receive clopidogrel and placebo (300- to 600-mg loading 
dose or continuation with a maintenance dose followed by 
75 mg per day) for 6 to 12 months. All patients were given 
aspirin. The primary composite endpoint was cardiovascular 
death, MI, or stroke. The primary composite end point 
occurred in fewer patients in the ticagrelor group than in 
the clopidogrel group (569 [event rate at 360 days, 9.0%] 
vs 668 [10.7%], hazard ratio 0.84, 95% CI 0.75–0.94; 
P = 0.0025). There was no difference between the 
clopidogrel and ticagrelor groups in the rates of total major 
bleeding (691 [11.6%] vs 689 [11.5%], 0.99 [0.89–1.10]; 
P = 0.8803) or severe bleeding, as defined according to 
the Global Use of Strategies To Open Occluded Coronary 
Arteries (GUSTO) trial, (198 [3.2%] vs 185 [2.9%], 0.91 
[0.74–1.12]; P = 0.3785). On the basis of the analysis of the 
use of a more potent ADP inhibitor in the setting of ACS 
and following an invasive strategy, ticagrelor appears to 
be the better option.21
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No genotypic limitations  
and superior platelet inhibition
Genetic polymorphisms can affect the platelet response 
to clopidogrel. Among these, CYP2C19 and ABCB1 
genotypes are known to influence the effects of clopidogrel; 
however, the CYP2C19 genotype does not influence the 
effects of ticagrelor.22 In a substudy of the PLATO trial,23 
a subgroup of patients underwent genotypic evaluation – 
10,285 of whom provided samples for genetic analysis. The 
primary outcome occurred less often with ticagrelor versus 
clopidogrel, irrespective of CYP2C19 genotype in patients 
with any loss-of-function allele (8.6% vs 11.2%, HR 0.77, 
95% CI 0.60–0.99; P = 0.0380) and in those without any 
  loss-  of-function allele (8.8% vs 10.0%, HR 0.86, 95% 
CI 0.74–1.01; P = 0.0608) (interaction P = 0.46). For the 
ABCB1 genotype, event rates for the primary outcome 
were also consistently lower in the ticagrelor group for all 
genotype groups (8.8% vs 11.9%, 95% CI 0.71, 0.55–0.92 
for the high-expression genotype) (interaction P = 0.39). 
In the clopidogrel group, the event rate at 30 days was 
higher in patients with loss-of-function CYP2C19 alleles 
than in those without (5.7% vs 3.8%; P = 0.028), leading to 
earlier separation of event rates between treatment groups 
for the patients with loss-of-function alleles. Patients on 
clopidogrel who had any gain-of-function CYP2C19 allele 
had a higher frequency of major bleeding (11.9%) than 
did those without any gain-of-function or loss-of-function 
alleles (9.5%; P = 0.022), but interaction between treatment 
and genotype groups was not significant for any type of 
major bleeding. Results of this study would suggest that 
ticagrelor is a more efficacious treatment for ACS than 
is clopidogrel, irrespective of CYP2C19 and ABCB1 
polymorphisms. The implementation of ticagrelor instead 
of clopidogrel would eliminate the need for the presently 
FDA-recommended genetic testing for suspected variability 
in response.
From the PLATO study, there is a platelet inhibition 
substudy. In this substudy, the inhibitory effects of ticagrelor 
were compared with clopidogrel during maintenance therapy, 
using light transmittance aggregometry and ADP as the 
agonist. It was documented that ticagrelor achieved greater 
suppression of platelet reactivity than clopidogrel. The 
mean maximum light transmittance aggregometry responses 
(ADP, 20 µM) after the maintenance dose were 44 ± 15% 
for clopidogrel and 28 ± 10% for ticagrelor (P , 0.001). 
High platelet reactivity was seen more frequently in the 
clopidogrel group. Proton-pump inhibitor use was associated 
with higher platelet reactivity with clopidogrel than with 
ticagrelor. The ticagrelor loading dose also achieved greater 
inhibition of platelet aggregation than did the clopidogrel 
loading dose. Therefore, the authors concluded that ticagrelor 
achieves a greater antiplatelet effect than does clopidogrel in 
ACS patients, both in the first hours of treatment and during 
maintenance therapy.24
Ticagrelor compared with other 
potent thienopyridines
To date, prasugrel and ticagrelor have not been directly 
compared. Biondi-Zoccai and colleagues25 attempted an 
indirect comparison meta-analysis adjusted by a common 
control that would enable indirect, adjusted, head-to-head 
comparisons of 2 treatments originally compared in con-
trolled trials to a common reference treatment. To compare 
prasugrel and ticagrelor in patients with ACS, 3 randomized 
trials were used, comprising a total of 32,893 patients: the 
DISPERSE-217 and the PLATO1 studies, both comparing 
ticagrelor and clopidogrel, and the TRITON-TIMI 38 study26 
comparing prasugrel and clopidogrel.
The overall pooled data for prasugrel and ticagrelor 
showed that prasugrel and ticagrelor were superior to 
clopidogrel in reducing the major clinical end points, without 
any significant difference in stroke or major bleeding, despite 
more frequent drug discontinuation. An indirect comparison 
of prasugrel and ticagrelor showed no significant differences 
in the risk of the main composite end point of death, MI, or 
stroke or of the individual components. However, risk of 
definite or probable stent thrombosis was significantly lower 
with prasugrel (odds ratio [OR] 95% CI, 0.64 [0.43–0.93]; 
P = 0.02, at the expense of a higher risk of any thrombolysis 
in myocardial infarction [TIMI] major bleeding, OR 95% 
CI 1.43 [1.10–1.85]; P = 0.007).25
Another indirect comparison of prasugrel (TRITON 
trial) and ticagrelor (PLATO trial) studied the metabolic 
side effects and efficacy profile.27 For metabolic side effects, 
ticagrelor increases levels of adenosine, suggesting that 
the impaired purine catabolism due to increased adenosine 
levels may cause elevated levels of serum creatinine and 
uric acid. This phenomenon has not been described with 
clopidogrel or prasugrel. This study shows that despite the 
fact that both the creatinine and uric acid levels return to 
pretreatment values after ticagrelor discontinuation, there is 
evidence that the alterations in purine metabolism are a real 
phenomenon, rather than a result of chance. Ticagrelor was 
clearly superior in efficacy to prasugrel for chronic preventive 
use because of absolute mortality reduction, realistic second 
MI prevention, growing over time vascular outcome benefit, Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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fewer hemorrhagic fatalities, potentially less CABG-related 
bleeding events, and lack of cancer risks.27
Limitations and side effects
A detailed evaluation of the study design and the inclusion and 
exclusion criteria of previous ticagrelor clinical trials reveals 
several limitations to the general applicability of results. 
These limitations may limit and subselect the population of 
patients who may safely receive this medication. Some of the 
exclusion criteria applied to patients in the ticagrelor studies 
may bring about concerns about pharmacologic or metabolic 
interactions, bleeding risk, cardiac rhythm and conduction 
effects, and overall compliance. Further, there should be 
careful evaluation and consideration of the side effects 
identified during the DISPERSE-2 and PLATO trials.
Metabolic interactions
Possible metabolic interactions that prompt patient exclusion 
from studies using ticagrelor include concomitant therapy with 
strong cytochrome P450 3A (CYP3A) inhibitors (ketoconazole, 
itraconazole, clarithromycin, indanivir, grapefruit juice), 
CYP3A substrates with narrow therapeutic indices 
(cyclosporine, simvastatin, lovastatin), and strong CYP3A 
inducers (rifampin, rifampicin, phenyotin, carbamazepine, 
phenobrabital). During PLATO, some unexplained metabolic 
findings showed an increased percentage at 12 months in 
the serum uric acid value from baseline in patients receiving 
ticagrelor compared with patients receiving clopidogrel 
(15 ± 52 vs 7 ± 31; P , 0.001). There was also a percentage 
increase in serum creatinine values from baseline values at 
12 months (11 ± 22 vs 9 ± 22; P , 0.001). Currently, the 
clinical impact of these metabolic changes is unknown, but 
they warrant careful registry and observation.1
Possible enhanced risk of bleeding
In clinical practice, some patients need chronic anticoagulant 
therapy; some have known bleeding diathesis or coagulation 
disorders; and some have a history of intracranial bleeding 
at any time, of gastrointestinal bleeding within the past 
6 months, or of major surgery within the last 30 days. Results 
of the PLATO trial showed an increase in fatal intracranial 
bleeding (0.1% vs 0.01%; P = 0.02); however, there were 
no significant differences compared with clopidogrel in 
life-threatening or fatal bleeding, by study criteria. There 
were also no differences in major bleeding or the need for 
red-cell transfusions.1
At this point, there are no recommendations on the 
  concomitant use of ticagrelor, aspirin, and warfarin. 
In patients with an ACS and valvular disease (mechanical 
valve replacement) or atrial fibrillation requiring chronic 
anticoagulation, the acquired experience with clopidogrel 
suggests that there is a definite increase in bleeding risk. 
To decrease that risk, the international normalized ratio 
should be lowered to between 2.0 and 2.5 and the concomitant 
administration of the 3 agents (clopidogrel, aspirin, and 
warfarin) limited to 3 months.
Possible effects on cardiac rhythm  
and conduction
Known risks include sick sinus syndrome and second- or 
third-degree atrioventricular block (unless already treated 
with a permanent pacemaker). In PLATO, the incidence 
of ventricular pauses .3 seconds identified during Holter 
  monitoring during the first week of therapy was 5.8% 
for patients given ticagrelor and 3.6% for patients given 
  clopidogrel (P = 0.01). There was no difference in the number 
of ventricular pauses at 30 days, the incidence of bradycardia, 
syncope or heart blocks, or the need for pacemaker insertion.1 
In the safety and tolerability evaluation of the DISPERSE-2 
trial, the post hoc analysis of continuous electrocardio-
grams showed that mostly asymptomatic ventricular pauses 
of .2.5 seconds were common with ticagrelor at dosages of 
180 mg twice daily but not at dosages of 90 mg twice daily 
when compared with clopidogrel.17
Possible noncompliance or poor 
compliance
Noncompliance or poor compliance may be due to the need 
for a twice-a-day administration. Given the increased use of 
drug-eluting stents and the need to maintain uninterrupted 
dual antiplatelet therapy in these cases, the discontinua-
tion of ticagrelor in the real world may lead to increased 
stent thrombosis or atherothrombotic events. The carefully 
selected patient population and continued surveillance that 
occurs during clinical trials may provide a false sense of 
security and increased compliance with therapy.
Dyspnea
In the PLATO study, there was an absolute 6% increase in 
the incidence of dyspnea (HR 1.84, 95% CI, 1.68–2.02; 
P , 0.001). Although dyspnea led to discontinuation of 
therapy in less than 1% of treated patients, its frequency 
and magnitude did achieve enough significance to be 
reported.1
Apparently, dyspnea while on ticagrelor is not related 
to abnormalities in pulmonary function tests. In the Core Evidence 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
40
Lombo and Díez
ONSET/OFFSET study,28 123 aspirin-treated patients with 
coronary artery disease who were in stable condition were 
randomly assigned to receive ticagrelor (180-mg loading 
dose followed by 90 mg twice daily), clopidogrel (600-mg 
loading dose   followed by 75 mg daily), or placebo. The inci-
dence of dyspnea was 38.6%, 9.3%, and 8.3%, respectively 
(P , 0.001). Three patients in the ticagrelor arm had to dis-
continue the medication because of dyspnea, while none in 
the clopidogrel or placebo arms did. There were no significant 
changes in echocardiographic or electrocardiographic find-
ings, serum N-terminal pro-brain natriuretic peptide values, 
or pulmonary function tests at baseline or 6 weeks after drug 
administration. Although the mechanism of dyspnea remains 
unknown, it appears to be related to adenosine-mediated 
stimulation of pulmonary C fibers. We do know that ticagrelor 
inhibits adenosine uptake by erythrocytes.29
Given the frequency of dyspnea as a side effect, with 
reports ranging from 6% to 38.6%, it may affect long-
term compliance if the agent is to be used routinely. For 
clinicians, it could be problematic during the recovery phase 
of ACS, because the presence of dyspnea could be confused 
with an angina equivalent, leading to further testing to 
exclude ischemia only to ascertain that it is produced by 
the administration of ticagrelor. As we expand the clinical 
use of ticagrelor and gain more experience, postmarketing 
evaluations may shed more light on dyspnea and its clini-
cal impact.
Differences in subgroups and populations
Another limitation of ticagrelor has been its lack of 
benefit in certain subgroups of patients in US trials. In 
the PLATO trial, there was no clear advantage to the use 
of ticagrelor over clopidogrel in patients with unstable 
angina. The lack of benefit observed in the US population 
was a main focus of the FDA’s meeting to consider approv-
ing ticagrelor. The PLATO trial showed a statistically 
insignificant trend toward worse outcomes with ticagrelor 
versus clopidogrel among US patients in the study – who 
comprised 1800 of the total 18,624 patients.1 When con-
sidering the composite end point of cardiovascular death, 
MI, or stroke, rates for the non-US patients were 9.6% 
for patients given ticagrelor and 11.8% for patients given 
clopidogrel (HR = 0.81). In the US population, this benefit 
was not seen. In fact, the HR actually reversed for the com-
posite end point: 12.6% for patients given ticagrelor and 
10.1% for patients given clopidogrel (HR = 1.27). Some 
believe the results could be due to differences in aspirin 
maintenance doses, which are higher in the United States, 
because that is the only variable that was correlated with 
different outcomes between the US and non-US patients. 
The FDA panelists generally agree that the aspirin factor 
is probably related to why the US patients did worse with 
ticagrelor, but they are not certain if that is because of a 
drug interaction or because the differences in aspirin main-
tenance dosages are a surrogate for some other unknown 
difference among patients. Still, the geographic differences 
in outcomes between different countries are difficult to 
explain, and those geographic differences in the results 
from the PLATO trial may have affected the overall results. 
Although chance may play a role, a prospective evalua-
tion of ticagrelor – once it is approved – will be required 
to see if the results from PLATO can be duplicated in the 
postmarketing phase.
What we know about ticagrelor 
therapy
Thienopyridines are a class of drugs that function by inhibit-
ing ADP P2Y12 platelet receptors. Currently, clopidogrel, 
a second-generation thienopyridine, is the main drug of 
choice, and the combination of aspirin and clopidogrel is 
administered orally for the treatment of ACS. As an alterna-
tive, the third-generation thienopyridine, prasugrel, has been 
approved for use in Europe and the US since 2009.
All thienopyridines, however, have pharmacologic 
limitations, and it is these limitations that have led to a search 
for more effective non-thienopyridine P2Y12 inhibitors. 
Promising results have been reported with ticagrelor, the first 
oral, reversible, direct-acting inhibitor of P2Y12 receptors 
that does not require metabolic activation. Furthermore, 
ticagrelor has at least 1 active metabolite, which is very 
similar pharmacokinetically to the parent compound. 
Therefore, ticagrelor has a more rapid onset and more 
pronounced platelet inhibition than do other antiplatelet 
agents.30
Ticagrelor selectively and reversibly blocks the P2Y12 
receptor, inhibiting platelet aggregation and preventing 
amplification of platelet activation. The optimal dosing 
strategy, as determined by ticagrelor’s pharmacokinetic 
and pharmacodynamic profile, is a loading dose of 180 mg 
followed by an oral dose of 90 mg twice daily. At these 
dosages, platelet inhibition is greater with ticagrelor than 
with clopidogrel (75 mg once daily) in both clopidogrel-
experienced and clopidogrel-naïve patients.
Ticagrelor is generally well tolerated; however, minor 
bleeding, dyspnea, hypotension, nausea, and ventricular 
pauses have been reported more frequently with ticagrelor Core Evidence 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
41
Ticagrelor as an oral antiplatelet treatment
than with clopidogrel.31 Reversible inhibition with ticagre-
lor may allow for more rapid surgical intervention after 
discontinuation, suggesting greater flexibility in the treat-
ment of ACS. However, a review of the literature (sup-
ported by the actual time to surgery that occurred during 
PLATO and the platelet inhibition [IPA] reported in the 
ONSET/OFFSET Study)32 suggests that there be at least 
3 days between the last dose of ticagrelor and surgery, 
but that is still shorter than the recommended 5 days for 
clopidogrel.
Conclusion
The options for drugs to inhibit the platelet P2Y12 receptor 
for ADP are rapidly expanding. In addition to ticlopidine and 
clopidogrel, other well-known compounds of proven anti-
thrombotic efficacy, including prasugrel, which has a higher 
potency and faster onset of action, have been approved for 
use in the setting of ACS. The direct and reversible P2Y12 
antagonist ticagrelor has shown benefits in clinical trials. Its 
rapid onset of platelet inhibition and short half-life make it 
an attractive alternative to thienopyridines, especially when 
rapid inhibition of platelet aggregation or its quick reversal 
are required.
We still have more to learn about the safety profile of 
ticagrelor. The data suggest that more powerful inhibition 
of the P2Y12 receptor is beneficial. However, it is the 
  clinician’s careful consideration when choosing from 
the available agents that will enable us to tailor the most 
appropriate antithrombotic therapy for patients. Given the 
remaining unknowns for chronic ticagrelor therapy and its 
expanded use in clinical practice, there is a need for careful 
postmarketing surveillance to better characterize its efficacy 
and safety profile.
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